Recombinant antibodies for the selective targeting of tumor neovasculature

Current Opinion in Drug Discovery and Development

Volumn 5, Issue 2, 2002, Pages 204-213

  Viti, Francesca ^a   Giovannoni, Leonardo ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Angiogenesis; Antibody engineering; Neovasculature; Recombinant antibodies; Tumor targeting

Indexed keywords

ALEMTUZUMAB; CAPROMAB PENDETIDE IN 111; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD44; MONOCLONAL ANTIBODY ED B; MONOCLONAL ANTIBODY LM 609; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; BIOTECHNOLOGY; CANCER; EYE DISEASE; GENE DELIVERY SYSTEM; GENE TARGETING; REVIEW; RHEUMATOID ARTHRITIS; TUMOR VASCULARIZATION;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; REGIONAL BLOOD FLOW;

EID: 0036489777     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy
2. Transport of molecules in the tumor interstitium: A review
3. Mechanisms of heterogenous distribution of monoclonal antibodies and other macromolecules in tumours: Significance of elevated interstitial pressure
4. Delivery of molecular and cellular medicine to solid tumors
5. Elucidation of the mechanism enabling tumor selective prodrug monotherapy
6. HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo
7. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
8. Efficacy of the chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma
9. Affinity reagents against tumor-associated extracellular molecules and newforming vessels
10. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors
11. Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model
12. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing
13. Tumor infarction by targeting tissue factor to tumor vasculature
14. Angiogenesis in cancer, vascular, rheumathoid and other disease
15. 2-regulated prolyl hydroxylation
16. 2, and the 3 PHDs: How animal cells signal hypoxia to the nucleus
17. Arteriogenesis, the good and bad of it
18. Vasculogenesis
19. Replacing the complementarity-determining regions in a human antibody with those from a mouse
20. Reshaping human antibodies for therapy
21. Making antibodies by phage display technology
22. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
23. Antibody fragments from a 'single pot' phage display library as immunochemical reagents
24. Design and use of phage display libraries for the selection of antibodies and enzymes
25. High-throughput generation and engineering of recombinant human antibodies
26. Generation of a large complex antibody library from multiple donors
27. Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries
28. Antibodies to human fetal erythroid cells from a non-immune phage antibody library
29. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies
30. Protein engineering by cell-surface display
31. MorphoSys-CAT fight
32. Therapeutic antibody production technologies: Molecules, applications, expression and purification
33. Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS)
34. Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening
35. Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies
36. Immunogenetic analysis of the immune response to pneumococcal polysaccharide
37. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coil
38. Engineering bispecific antibodies
39. 'Diabodies': Small bivalent and bispecific antibody fragments
40. A comparison of strategies to stabilize immunoglobulin Fv-fragments
41. Engineering antibody Fv fragments for cancer detection and therapy: Disulfide-stabilized Fv fragments
42. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts
43. Mammalian cell expression of dimeric small immune proteins (SIP)
44. Secreted and cell surface genes expressed in benign and malignant colorectal tumors
45. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules
46. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
47. Involvement of integrins αvβ3 and αvβ5 in ocular neovascular diseases
48. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
49. Immunohistochemical analysis of integrin αvβ3 expression on tumor-associated vessels of human carcinomas
50. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer
51. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells
52. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions
53. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies
54. 125I-labeled anti-endoglin monoclonal antibodies
55. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin
56. Endoglin is a suitable target for efficient imaging of solid tumors: In vivo evidence in a canine mammary carcinoma model
57. Lack of specificity of endoglin expression for tumor blood vessels
58. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: Implications for diagnosis and therapy
59. VEGF: An update on biological and therapeutic aspects
60. Vascular endothelial growth factor as a marker of tumor endothelium
61. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
62. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor
63. A strategy for antitumor vascular therapy by targeting the vascular endothelial growth factor: Receptor complex
64. Tumor targeting properties of antibody-VEGF fusion proteins
65. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium
66. Prostate-specific membrane antigen is produced in tumor-associated neovasculature
67. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
68. CD44 is involved in tumor angiogenesis; an activation antigen on human endothelial cells
69. The role of angiogenesis, laminin and CD44 expression in metastatic behavior of early-stage low-grade invasive breast carcinomas
70. Molecular cloning and characterization of antigens expressed on rat tumor vascular endothelial cells
71. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy
72. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon
73. The fibronectin isoform containing the ED-B oncofetal domain: A marker of angiogenesis
74. Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues
75. Selective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragment
76. Expression of fibronectin ED-A+ and ED-B+ isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts
77. Interstitial collagenase and the ED-B oncofetal domain of fibronectin are markers of angiogenesis in human skin tumors
78. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
79. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel
80. NMR structure of the human oncofoetal fibronectin ED-B domain, a specific marker for angiogenesis
81. A high-affinity human antibody that targets tumoral blood vessels
82. Selective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectin
83. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
84. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody
85. Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies
86. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts
87. Astatine-211-labeled radiotherapeutics: An emerging approach to targeted α-particle radiotherapy
88. Tumor therapy with targeted atomic nanogenerators
89. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
90. Enhancement of the anti-tumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
91. Enhancement of the anti-tumor activity of interleukin-12 by targeted delivery to neo-vasculature
92. Identifying the proportion of age related macular degeneration patients who would benefit from photodynamic therapy with verteporfin (Visudyne)
93. Transmittance of non-ionizing radiation in human tissues
94. Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer
95. Human single-chain Fv immunoconjugates targeted to a melanoma-associated chondroitin sulfate proteoglycan mediate specific lysis of human melanoma cells by natural killer cells and complement
96. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display